<?xml version="1.0" encoding="UTF-8"?>
<p>Cynomolgus monkeys inoculated with an attenuated EV-A71 vaccine showed mild neurological symptoms but survived lethal challenge by virulent EV-A71 (BrCr-TR) without exacerbation of symptoms 
 <xref rid="B51" ref-type="bibr">
  <sup>51</sup>
 </xref> . Although this study indicated that the monkeysâ€™ immunization with attenuated EV-A71 vaccine had the potential to produce significant titers of neutralized antibodies against different genogroups of EV-A71, including A, B1, B4, C2 and C4 
 <xref rid="B51" ref-type="bibr">
  <sup>51</sup>
 </xref> , several safety issues concerning live-attenuated virus vaccines need to be overcome. For example, immunization with the attenuated strain might cause mild neurological symptoms when inoculated via the intravenous route. However, a high-fidelity variant of EV-A71 exhibited an attenuated phenotype and showed an intriguing potential as a live-attenuated EV-A71 vaccine 
 <xref rid="B52" ref-type="bibr">
  <sup>52</sup>
 </xref> .
</p>
